Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments

  1. Zan He
  2. Zijuan Xin
  3. Qiong Yang
  4. Chen Wang
  5. Meng Li
  6. Wei Rao
  7. Zhimin Du
  8. Jia Bai
  9. Zixuan Guo
  10. Xiuyan Ruan
  11. Zhaojun Zhang
  12. Xiangdong Fang  Is a corresponding author
  13. Hua Zhao  Is a corresponding author
  1. General Hospital of People's Liberation Army, China
  2. Chinese Academy of Sciences, China

Abstract

Acral melanoma (AM) exhibits a high incidence in Asian patients with melanoma, and it is not well treated with immunotherapy. However, little attention has been paid to the characteristics of the immune microenvironment in AM. Therefore, in this study, we collected clinical samples from Chinese patients with AM and conducted single-cell RNA sequencing to analyze the heterogeneity of its tumour microenvironments (TMEs) and the molecular regulatory network . Our analysis revealed that genes, such as TWIST1, EREG, TNFRSF9, and CTGF could drive the deregulation of various TME components. The molecular interaction relationships between TME cells, such as MIF-CD44 and TNFSF9-TNFRSF9, might be an attractive target for developing novel immunotherapeutic agents.

Data availability

Sequencing data have been deposited in GSA under accession codes HRA001804.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Zan He

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Zijuan Xin

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Qiong Yang

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Chen Wang

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  5. Meng Li

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Wei Rao

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Zhimin Du

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Jia Bai

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  9. Zixuan Guo

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  10. Xiuyan Ruan

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  11. Zhaojun Zhang

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  12. Xiangdong Fang

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    For correspondence
    fangxd@big.ac.cn
    Competing interests
    The authors declare that no competing interests exist.
  13. Hua Zhao

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    For correspondence
    hualuck301@163.com
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7139-1844

Funding

National Natural Science Foundation of China (81672698)

  • Hua Zhao

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: All samples were obtained from the General Hospital of the People's Liberation Army, Beijing, China. All volunteers signed informed consent prior to sample acquisition. Four primary AM tissues, three paracancerous tissues, and a metastatic lymph gland sample were included in this cohort. This study was approved by the Ethics Committee of Chinese PLA General Hospital and complied with all relevant ethical regulations(Approval No. S2021-626).

Copyright

© 2022, He et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,929
    views
  • 414
    downloads
  • 11
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zan He
  2. Zijuan Xin
  3. Qiong Yang
  4. Chen Wang
  5. Meng Li
  6. Wei Rao
  7. Zhimin Du
  8. Jia Bai
  9. Zixuan Guo
  10. Xiuyan Ruan
  11. Zhaojun Zhang
  12. Xiangdong Fang
  13. Hua Zhao
(2022)
Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments
eLife 11:e78616.
https://doi.org/10.7554/eLife.78616

Share this article

https://doi.org/10.7554/eLife.78616

Further reading

    1. Cancer Biology
    Yumin Fu, Xinyu Guo ... Lianxin Liu
    Review Article

    Hepatocellular carcinoma (HCC), the most common type of liver tumor, is a leading cause of cancer-related deaths, and the incidence of liver cancer is still increasing worldwide. Curative hepatectomy or liver transplantation is only indicated for a small population of patients with early-stage HCC. However, most patients with HCC are not candidates for radical resection due to disease progression, leading to the choice of the conventional tyrosine kinase inhibitor drug sorafenib as first-line treatment. In the past few years, immunotherapy, mainly immune checkpoint inhibitors (ICIs), has revolutionized the clinical strategy for HCC. Combination therapy with ICIs has proven more effective than sorafenib, and clinical trials have been conducted to apply these therapies to patients. Despite significant progress in immunotherapy, the molecular mechanisms behind it remain unclear, and immune resistance is often challenging to overcome. Several studies have pointed out that the complex intercellular communication network in the immune microenvironment of HCC regulates tumor escape and drug resistance to immune response. This underscores the urgent need to analyze the immune microenvironment of HCC. This review describes the immunosuppressive cell populations in the immune microenvironment of HCC, as well as the related clinical trials, aiming to provide insights for the next generation of precision immunotherapy.

    1. Cancer Biology
    2. Genetics and Genomics
    Li Min, Fanqin Bu ... Shutian Zhang
    Research Article

    It takes more than 20 years for normal colorectal mucosa to develop into metastatic carcinoma. The long time window provides a golden opportunity for early detection to terminate the malignant progression. Here, we aim to enable liquid biopsy of T1a stage colorectal cancer (CRC) and precancerous advanced adenoma (AA) by profiling circulating small extracellular vesicle (sEV)-derived RNAs. We exhibited a full RNA landscape for the circulating sEVs isolated from 60 participants. A total of 58,333 annotated RNAs were detected from plasma sEVs, among which 1,615 and 888 sEV-RNAs were found differentially expressed in plasma from T1a stage CRC and AA compared to normal controls (NC). Then we further categorized these sEV-RNAs into six modules by a weighted gene coexpression network analysis and constructed a 60-gene t-SNE model consisting of the top 10 RNAs of each module that could well distinguish T1a stage CRC/AA from NC samples. Some sEV-RNAs were also identified as indicators of specific endoscopic and morphological features of different colorectal lesions. The top-ranked biomarkers were further verified by RT-qPCR, proving that these candidate sEV-RNAs successfully identified T1a stage CRC/AA from NC in another cohort of 124 participants. Finally, we adopted different algorithms to improve the performance of RT-qPCR-based models and successfully constructed an optimized classifier with 79.3% specificity and 99.0% sensitivity. In conclusion, circulating sEVs of T1a stage CRC and AA patients have distinct RNA profiles, which successfully enable the detection of both T1a stage CRC and AA via liquid biopsy.